Please login to the form below

Not currently logged in
Email:
Password:

Gilead sells rights for cancer drug DaunoXome to Galen

First steps into both the US and the oncology markets for Northern Ireland-based pharma firm

Gilead Sciences has sold the rights for its chemotherapy DaunoXome to Northern Ireland-based Galen Pharmaceuticals.

The acquisition, the value of which remains undisclosed, will be the company's first steps into the both the cancer market and the US.

Previously Galen's focus had been on marketing branded and generic prescription medicines in the UK and Ireland in COPD, urology and pain management.

DaunoXome (daunorubicin citrate liposome injection) is an anthracycline chemotherapy used to treat for advanced HIV-associated Kaposi's sarcoma, a type of cancer that usually affects the skin and mouth, and is caused by human herpes virus 8 (HHV8).

Most people living with the virus don't get Kaposi's sarcoma, however, people with weakened immune systems, such as those living with HIV, are more susceptible to it.

President of Galen Mark Scrutton said: "We are delighted that we are now able to supply DaunoXome in the US for the treatment of patients with this devastating disease.

“DaunoXome marks our first step into the oncology arena and this exciting, new acquisition provides us with the opportunity to offer more widely a much-needed therapy for patients with advanced HIV-associated KS."

As well as the US, Galen will market DaunoXome in 12 European countries and Brazil.

Galen's other products include Flotros for incontinence, Saline Steripoules to nebulise COPD and asthma treatments, and Uracyst to repair damaged bladders.

24th February 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Five key trends in precision and personalised healthcare
Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...
Language barriers: Obesity has become a loaded word
...

Infographics